Transcript Pharmacoeconomics – Polish Perspective

ISPOR POLAND CHAPTER
Polish Society of
Pharmacoeconomics (PTFe )
Accepted
International
examples
multidisciplinary
methodology
Pharmacoeconomics
in
Poland
Optimizing pharmacotherapy through rational drugs
management
Pharmacoeconomics in Poland
Regulations
Methodology/
Standardization
Polish
terminology
Educational
opportunities
Existing
resources
REGULATIONS
1.
Act on Health Services Financed from Public Sources
a)
Necessity of justyfying proposed price
b)
Evidence on clinical efficiacy, cost- effectiveness and budget impact analysis
(for innovative drugs)
2.
Act on Prices
3.
Regulations concerning Health Technology Assessment Agency
4.
a)
Economic evaluation including cost analysis
b)
Influence on financing from public sources
Requirements concerning Treatment Programmes financed by the
National Health Fund
a)
Defining cost-endpoint relationship
METHODOLOGY/TERMINOLOGY
1.
Polish Guidlines for conducting pharmacoeconomic
evaluations (2000) approved by ISPOR Polish Chapter
2.
The Polish Dictionary of Pharmacoeconomics 1st and 2nd
editions
3.
Textbooks and manuals
REIMBURSEMENT SYSTEM
Limit prices for reimbursed drugs
The same active
substance, different
market price.
Generic limit
price
Different active substances,
the same effect, different
market price.
Basic and
supplementary
list
Fixed charge
Therapeutic limit
price
70%
50%
ISPOR POLAND CHAPTER in 2005-2006

Organizing the 3rd Scientific Conference of the Polish Society of
Pharmacoeconomics: („Reimbursement systems in EU countries; discussion
about activities of the Society members in working groups of ISPOR
1.
Working on the 4th Scientific Conference of the Polish Society of
Pharmacoeconomics (focused on : pharmacoeconomics and economic evaluation
of heath care programs; prof. Paul Kind as a main speaker: “Patient reported
outcomes and quality of life”; inviting Czech and Russian ISPOR Chapters
Presidents
2.
Creating Student Section within the Polish Society of Pharmacoeconomics with 25
members in order to promote interest and awareness about pharmacoeconomics,
health outcome research to various disciplines across members of health-related
organizations and universities in Poland
3.
Educational support of Student Section by PTFE – lectures
–
„Pharmacoeconomics in Polish perspective”
–
„Health and economics” prof. Tomasz Hermanowski
ISPOR POLAND CHAPTER in 2005-2006
1.
Cooperation with medical societies in educational area – lectures on
pharmacoeconomics for relevant scientific and medical societies
2.
Discussion with representatives of the Ministry of Health about principles of pricing
and reimbursement system in Poland in relation to pharmacoeconomics
3.
Discussion with the Association of Pharmaceutical Industry in Poland on the Code
of Marketing Ethics.
 Stating an objection against the use of pharmacoeconomic studies as a marketing tool.
4.
Representing the Polish Society of Pharmacoeconomics on the following
conferences:
 the 7th Congress of European Association for Clinical Pharmacology and Thearpautics”
 Lectures about the role of pharmacoeconomics in drug policy,
 Conference of Quality Management Center, Cracow,
 Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment
process”, Oct. 2006
 participation in experts panel „How clinical trials for new drugs should be financing?”, Oct.
2006